ScholarGate
Trợ lý

So sánh phương pháp

Xem các phương pháp đã chọn cạnh nhau; những hàng khác biệt được làm nổi bật.

Thử nghiệm lâm sàng Giai đoạn II×Thử nghiệm lâm sàng Giai đoạn I×
Lĩnh vựcDịch tễ họcDịch tễ học
HọProcess / pipelineProcess / pipeline
Năm ra đời1960s–1970s (formalised in US federal drug regulation)1960s (formal regulatory framework established ~1963–1970s)
Người khởi xướngU.S. Food and Drug Administration / ICH E8 guidelines (institutionalised framework)Regulatory and clinical pharmacology community; formalized in U.S. FDA IND regulations (1963) and ICH guidelines
LoạiInterventional clinical study designInterventional clinical study design
Công trình gốcFriedman, L. M., Furberg, C. D., DeMets, D. L., Reboussin, D. M., & Granger, C. B. (2015). Fundamentals of Clinical Trials (5th ed.). Springer. ISBN: 978-3319185392Storer, B. E. (1989). Design and analysis of phase I clinical trials. Biometrics, 45(3), 925–937. DOI ↗
Tên gọi khácPhase 2 trial, Phase II study, early efficacy trial, proof-of-concept trialPhase 1 trial, first-in-human study, FIH study, dose-escalation study
Liên quan66
Tóm tắtA Phase II clinical trial is the second stage in the drug or intervention development pipeline, conducted after Phase I safety testing. Its primary goal is to assess whether the intervention shows preliminary efficacy signals in a relevant patient population at the dose established in Phase I, while continuing to characterise the safety and tolerability profile. Phase II trials are generally smaller than Phase III confirmatory trials and serve as critical go/no-go decision points before large-scale investment.A Phase I clinical trial is the first stage of human testing for a new drug, biologic, or intervention. Its primary objective is to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) rather than therapeutic efficacy. Small cohorts of participants — typically healthy volunteers or patients with advanced disease — receive sequentially increasing doses to identify the maximum tolerated dose (MTD) and the dose-limiting toxicities (DLTs) that define the boundary for subsequent trials.
ScholarGateBộ dữ liệu
  1. v1
  2. 2 Nguồn tài liệu
  3. PUBLISHED
  1. v1
  2. 2 Nguồn tài liệu
  3. PUBLISHED

Đến trang tìm kiếm Tải xuống bản trình chiếu

ScholarGateSo sánh phương pháp: Phase II clinical trial · Phase I Clinical Trial. Truy cập ngày 2026-06-20 từ https://scholargate.app/vi/compare